Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Opium (Opioid) Addiction develops after using opioids regularly for a period. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). Its signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping, and pain in the bones. The predisposing factors include age, personal history/ family history of substance abuse, cigarette dependency, and psychological stress.
The Opium Addiction pipeline market research report provides comprehensive information on the therapeutics under development for Opium Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium Addiction and features dormant and discontinued projects.
Key Targets in the Opium Addiction Pipeline Products Market
The key targets in the Opium Addiction pipeline products market are Mu Type Opioid Receptor, Kappa Type Opioid Receptor, Delta Type Opioid Receptor, Opioid Receptor, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glutamate Ionotropic Receptor NMDA Type Subunit, Aldehyde Dehydrogenase, Neuronal Acetylcholine Receptor Subunit Alpha 3, Neuronal Acetylcholine Receptor Subunit Beta 4, and others.
Opium Addiction Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Opium Addiction Pipeline Products MarketThe key mechanisms of action in the Opium Addiction pipeline products market are Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Agonist, Delta Type Opioid Receptor Antagonist, Opioid Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Delta Type Opioid Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, and others.
The key mechanisms of action in the Opium Addiction pipeline products market are Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Agonist, Delta Type Opioid Receptor Antagonist, Opioid Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Delta Type Opioid Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, and others.
Opium Addiction Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Opium Addiction Pipeline Products Market
The key routes of administration in the Opium Addiction pipeline products market are oral, subcutaneous, sublingual, intravenous, intramuscular, parenteral, transdermal, injection, nasal, buccal, and inhalational.
Opium Addiction Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Opium Addiction Pipeline Products Market
The key molecule types in the Opium Addiction pipeline products market are small molecule, conjugate vaccine, antibody, gene therapy, monoclonal antibody, synthetic peptide, and vaccine.
Opium Addiction Pipeline Products Market Analysis by Molecule Types
For more molecule type insights, download a free report sample
Major Companies in the Opium Addiction Pipeline Products Market
Some of the major companies in the Opium Addiction pipeline products market are BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals Inc, Cessation Therapeutics LLC, Gilgamesh Pharmaceuticals Inc, Indivior Plc, Lyndra Therapeutics Inc., Mind Medicine MindMed Inc, and Nirsum Laboratories Inc.
Opium (Opioid) Addiction Pipeline Products Market Report Overview
Key Targets | Mu Type Opioid Receptor, Kappa Type Opioid Receptor, Delta Type Opioid Receptor, Opioid Receptor, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glutamate Ionotropic Receptor NMDA Type Subunit, Aldehyde Dehydrogenase, Neuronal Acetylcholine Receptor Subunit Alpha 3, Neuronal Acetylcholine Receptor Subunit Beta 4, and Others |
Key Mechanisms of Action | Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Agonist, Delta Type Opioid Receptor Antagonist, Opioid Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Delta Type Opioid Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, and Others |
Key Routes of Administration | Oral, Subcutaneous, Sublingual, Intravenous, Intramuscular, Parenteral, Transdermal, Injection, Nasal, Buccal, and Inhalational |
Key Molecule Type | Small Molecule, Conjugate Vaccine, Antibody, Gene Therapy, Monoclonal Antibody, Synthetic Peptide, and Vaccine |
Major Companies | BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals Inc, Cessation Therapeutics LLC, Gilgamesh Pharmaceuticals Inc, Indivior Plc, Lyndra Therapeutics Inc., Mind Medicine MindMed Inc, and Nirsum Laboratories Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Alar Pharmaceuticals Inc
Amygdala Neurosciences Inc
Ananda Scientific Inc
Antheia Inc
Aoxing Pharmaceutical Company Inc
Aphios Corp
Aquilus Pharmaceuticals Inc
Atai Life Sciences NV
Benuvia Therapeutics Inc
BioCorRx Inc
BioXcel Therapeutics Inc
Bridge Therapeutics Inc
Bright Minds Biosciences Inc
Camurus AB
Ceruvia Lifesciences LLC
Cessation Therapeutics LLC
Copernicus Therapeutics Inc
Creative Bio-Peptides Inc
Delpor Inc
DemeRx Inc
DMK Pharmaceuticals Inc
Elysium Therapeutics Inc
Emergent BioSolutions Inc
Ensysce Biosciences Inc
Eolas Therapeutics Inc
Epiodyne Inc
Ethismos Research Inc
Exxel Pharma Inc
Fab’entech SA
Fannin Partners LLC
Gilgamesh Pharmaceuticals Inc
Hunan Saiao Pharmaceutical Co Ltd
Indivior Plc
Inimmune Corp
Jazz Pharmaceuticals Plc
Kinoxis Therapeutics Pty Ltd
Lyndra Therapeutics Inc.
Mayne Pharma Group Ltd
Mebias Discovery LLC
Mind Medicine MindMed Inc
Nirsum Laboratories Inc
Omeros Corp
Opiant Pharmaceuticals Inc
Orexo AB
Orphomed Inc
Osmotica Pharmaceutical Corp
OYE Therapeutics Inc
Palisades Therapeutics
Phoenix PharmaLabs Inc
Plumb Pharmaceuticals LLC
Revive Therapeutics Ltd
SafeRX Pharmaceuticals Inc
Sen-Jam Pharmaceutical LLC
Senzer Ltd
Serina Therapeutics Inc
Sparian Biosciences Inc
Syntropharma Ltd
Titan Pharmaceuticals Inc
VDM Biochemicals Inc
Vivreon Biosciences LLC
Yichang Humanwell Pharmaceutical Co Ltd
Zynerba Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Opium Addiction products market?
The key targets in the Opium Addiction pipeline products market are Mu Type Opioid Receptor, Kappa Type Opioid Receptor, Delta Type Opioid Receptor, Opioid Receptor, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glutamate Ionotropic Receptor NMDA Type Subunit, Aldehyde Dehydrogenase, Neuronal Acetylcholine Receptor Subunit Alpha 3, Neuronal Acetylcholine Receptor Subunit Beta 4, and others.
-
What are the key mechanisms of action in the Opium Addiction pipeline products market?
The key mechanisms of action in the Opium Addiction pipeline products market are Mu Type Opioid Receptor Agonist, Mu Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Antagonist, Kappa Type Opioid Receptor Agonist, Delta Type Opioid Receptor Antagonist, Opioid Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Delta Type Opioid Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Antagonist, and others.
-
What are the key routes of administration in the Opium Addiction pipeline products market?
The key routes of administration in the Opium Addiction pipeline products market are oral, subcutaneous, sublingual, intravenous, intramuscular, parenteral, transdermal, injection, nasal, buccal, and inhalational.
-
What are the key molecule types in the Opium Addiction pipeline products market?
The key molecule types in the Opium Addiction pipeline products market are small molecule, conjugate vaccine, antibody, gene therapy, monoclonal antibody, synthetic peptide, and vaccine.
-
Which are the major companies in the Opium Addiction pipeline products market?
Some of the major companies in the Opium Addiction pipeline products market are BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals Inc, Cessation Therapeutics LLC, Gilgamesh Pharmaceuticals Inc, Indivior Plc, Lyndra Therapeutics Inc., Mind Medicine MindMed Inc, and Nirsum Laboratories Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.